Alemtuzumab

被引：49

作者：

Ravandi, F ^{[1
]}

O'Brien, S ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2005年 / 5卷 / 01期

关键词：

alemtuzumab; immune suppression; lymphoid malignancies; therapy;

D O I：

10.1586/14737140.5.1.39

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Alemtuzumab Is a humanized monoclonal antibody against CD52, a small glycosylphosphatidylinositol-anchored glycoprotein that Is highly expressed on normal T- and B-lymphocytes, and on a large proportion of malignant lymphold cells, but not on hematopoletic progenitor cells. Over the past several years, a number of clinical trials have demonstrated the clinical activity of alemtuzumab in treating patients with chronic lymphocytic leukemia, T-cell malignancies such as T-prolymphocytic leukemia and cutaneous T-cell lymphoma, as well as In the prevention and therapy of graft-versus-host disease In the setting of allogenelc stem cell transplantation. Its application In a number of autoimmune disorders Is currently under Investigation. The most significant side effect of alemtuzumab Is predisposition to Infections related to the associated profound lymphopenla. Despite this, and with appropriate and more effective antibiotic prophylaxis, It Is likely that we will witness an expansion of the role of alemtuzumob In the future.

引用

页码：39 / 51

页数：13

共 91 条

[31] THE GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED LYMPHOCYTE ANTIGEN CDW52 IS ASSOCIATED WITH THE EPIDIDYMAL MATURATION OF HUMAN SPERMATOZOA [J].

HALE, G ;

RYE, PD ;

WARFORD, A ;

LAUDER, I ;

BRITOBABAPULLE, A .

JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 1993, 23 (02) :189-205

[32] Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nomnyeloablative conditioning? [J].

Hale, G ;

Slavin, S ;

Goldman, JM ;

Mackinnon, S ;

Giralt, S ;

Waldmann, H .

BONE MARROW TRANSPLANTATION, 2002, 30 (12) :797-804

[33] T-CELL DEPLETION WITH CAMPATH-1 IN ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].

HALE, G ;

COBBOLD, S ;

WALDMANN, H .

TRANSPLANTATION, 1988, 45 (04) :753-759

[34] Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection [J].

Hale, G ;

Zhang, MJ ;

Bunjes, D ;

Prentice, HG ;

Spence, D ;

Horowitz, MM ;

Barrett, AJ ;

Waldmann, H .

BLOOD, 1998, 92 (12) :4581-4590

[35]

HALE G, 1983, BLOOD, V62, P873

[36]

HALE G, 1994, BONE MARROW TRANSPL, V13, P597

[37]

Hale G, 1983, Mol Biol Med, V1, P321

[38]

Isaacs J D, 1990, Semin Immunol, V2, P449

[39] 1.9 Å structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen [J].

James, LC ;

Hale, G ;

Waldman, H ;

Bloomer, AC .

JOURNAL OF MOLECULAR BIOLOGY, 1999, 289 (02) :293-301

[40]

JORDAN MB, 2004, IN PRESS PEDIAT BLOO

← 1 2 3 4 5 6 7 8 9 10 →